4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Dermatology by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 3028 ongoing clinical trials involving Dermatology
Of the 3028 trials,1033 trials are in Phase III
Furthermore, 942 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Dermatology by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Dermatology therapy area. The largest number of ongoing clinical trials for Dermatology therapy area is conducted in the Asia-Pacific region. North America and Europe are among some of the other prominent regions involved in Dermatology-related drug trials.

Novartis AG: The leading ongoing Dermatology related clinicaltrialsponsor

Novartis AG, the Switzerland based pharmaceutical company, is the top sponsor for Dermatology-related ongoing clinical trials.

Galderma SA, Eli Lilly and Co, Isfahan University of Medical Sciences, and Pfizer Inc are a few other notable clinicaltrial sponsors involving Dermatology. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Dermatology

Dupilumab (REGN-668, SAR231893, Dupixent, Dubrantis), Upadacitinib (Rinvoq, Rim-Voq), and Onabotulinumtoxin A (Botox) are among the key marketed drugs involving Dermatology.

Dupilumab (REGN-668, SAR231893, Dupixent, Dubrantis) is a monoclonal antibody developed based on VelocImmune technology. It functions via Interleukin 4 Receptor Subunit Alpha (CD124 or IL4R) Antagonist mechanism of action.It is formulated as an injectable solution and injectable powder for solution for subcutaneous route of administration. Dupilumabwas first approved in 2017 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by several prominent pharma giants including Sanofi-Aventis US LLC.

Upadacitinib (Rinvoq, Rim-Voq) is an antineoplastic drug, acts as immunosuppressive agent. It functions via Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Inhibitormechanism of action.  It is formulated as extended release tablets, extended release coated tablets and extended release film coated tablets for oral route of administration.Upadacitinib was first approved in 2019 and is marketed globally including the US, the UK, France, Germany, and Japan by AbbVie Inc.